8-K current report · filed Oct 30, 2026

Azenta, Inc. (AZTA) 8-K Current Report: October 30, 2026

Item 1.01Item 8.01Item EX-99.1Item 7.01AZTA overview

Short answer

Azenta, Inc. (AZTA) filed an 8-K current report with the SEC on October 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Exclusive, royalty-free Elegen gene-synthesis license expands GENEWIZ manufacturing and global service capabilities.

Azenta, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Exclusive, royalty-free Elegen gene-synthesis license expands GENEWIZ manufacturing and global service capabilities
  • Initial license term five years, with conversion option to perpetual exclusive rights for $25 million
  • Total contemplated capital deployment approximately $32 million to $71 million
  • Elegen supply agreement secures proprietary consumables, training and process-development support
  • Retained Elegen rights and change-of-control protections limit full exclusivity exposure

Item 7.01 · Regulation FD Disclosure

  • October 30, 2026 press release announces Azenta’s acquisition of SynPlexity
  • Release also highlights contractual arrangements with Elegen
  • Investors should assess transaction terms and strategic impact under Items 1.01 and 8.01

Item 8.01 · Other Events

  • Azenta acquired all SynPlexity shares on October 28, 2026, expanding its DNA assembly capabilities
  • SynPlexity technology targets large, multiplexed gene libraries for screening, drug discovery and therapeutics
  • Integration into GENEWIZ could broaden offerings, markets and construct complexity
  • Separate SynPlexity and Elegen transactions increase execution dependence on technology transfer, scaling and supply continuity
  • Expected benefits remain uncertain, with risks from integration, customer adoption, deployment costs and competition

Item EX-99.1 · Exhibit EX-99.1

  • Exclusive Elegen license adds cell-free DNA synthesis, targeting higher quality, faster delivery, and scalable regional production
  • SynPlexity acquisition adds pooled assembly libraries with thousands of full-length gene variants for high-throughput discovery
  • Strategic expansion targets synthetic biology, protein engineering, and AI-enabled drug discovery through GENEWIZ
  • Financial terms and expected contribution remain pending Azenta’s fourth-quarter fiscal 2026 earnings call
  • Execution risks include technology integration, validation, scalability, intellectual-property protection, and customer adoption

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Azenta, Inc. 8-K filings

Get the next AZTA 8-K as it lands

Follow AZTA for push alerts, or ask the research agent what this filing means.